Advertisement
UK markets close in 6 hours 33 minutes

  • FTSE 100

    8,242.30
    -11.88 (-0.14%)
     

  • FTSE 250

    20,642.65
    -62.62 (-0.30%)
     

  • AIM

    806.42
    -1.94 (-0.24%)
     

  • GBP/EUR

    1.1771
    +0.0016 (+0.13%)
     

  • GBP/USD

    1.2756
    -0.0015 (-0.12%)
     

  • Bitcoin GBP

    53,157.78
    -209.77 (-0.39%)
     

  • CMC Crypto 200

    1,459.47
    -25.22 (-1.70%)
     

  • S&P 500

    5,306.04
    +1.32 (+0.02%)
     

  • DOW

    38,852.86
    -216.74 (-0.55%)
     

  • CRUDE OIL

    80.56
    +0.73 (+0.91%)
     

  • GOLD FUTURES

    2,347.20
    -9.30 (-0.39%)
     

  • NIKKEI 225

    38,556.87
    -298.50 (-0.77%)
     

  • HANG SENG

    18,477.01
    -344.15 (-1.83%)
     

  • DAX

    18,615.01
    -62.86 (-0.34%)
     

  • CAC 40

    8,015.10
    -42.70 (-0.53%)
     
Money:

What's best?

Should you support your children at university or help them on to property ladder?

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
·1-min read
Zealand Pharma
Zealand Pharma

Company announcement – No. 25 / 2024

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, Denmark, May 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

ADVERTISEMENT

Please see the attached file(s).

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnership agreements with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contact:

Anna Krassowska
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com

Adam Lange
Investor Relations Officer
Zealand Pharma
Email: akl@zealandpharma.com

Attachment